Moreover, deficit mutations in checkpoint kinase 2 (CHEK2), an important gene in the DDR, enhance the antitumor effect of anti-PD-1 therapy, as shown in mice with MC38 and B16 tumors, by affecting the tumor immunological microenvironment [110]. The gene discussed is CHEK2; the disease is neoplasm.